Cleveland Clinic Taussig Cancer Institute
M

Targeting Actionable Mutations in Myeloid Malignancies: To Target or Not?

By Cleveland Clinic Taussig Cancer Institute FEATURING Mark Levis
By Cleveland Clinic Taussig Cancer Institute FEATURING Mark Levis
160 views
December 12, 2018
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Related Content

AUTOPLAY
19:10
5th SOHO Italy Annual Conference

SOHO Italy 2023: How I Treat AML at MD Anderson Cancer Center

Feat. H. Kantarjian
12:33
SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: AML

Feat. H. Kantarjian
44:26
University of Colorado Division of Hematology

Novel Therapies in AML and MDS

Feat. D. Pollyea
13:39
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Triplet Regimens in AML: Beyond Azacitidine + Venetoclax

Feat. C. DiNardo
22:30
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Emerging Treatment Options for AML in 2024

Feat. A. Perl
14:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Immunotherapies in Acute Leukemias: 2024 Update

Feat. C. Lai
32:04
Moffitt Cancer Center

Experts Discuss the Latest Data in Myeloid Diseases

Feat. A. Kuykendall, R. Komrokji, O. Chan, D. Sallman
19:51
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

A 50-Year Personal Perspective on the Treatment of AML

Feat. C. Schiffer
11:41
Penn Medicine Abramson Cancer Center

Penn Medicine Updates From Recent Meetings in Hematologic Malignanci…

Feat. C. Lai
10:41
ASH 2022 Conference Coverage

ASH 2022 Triplet Combination of Azacitidine, Venetoclax, and Gilteri…

Feat. N. Short
10:31
SOHO Turkey 2023

SOHO Turkey 2023: How I Treat AML

Feat. F. Ravandi
15:57
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: What Is the Future of Menin Inhibitors in AML?

Feat. G. Issa
21:20
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "The Future Paradigm of HMA + Ven or Targete…

Feat. J. Watts
16:02
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Managing the Toxicities and Supportive Ca…

Feat. G. Mannis
04:36
Suresh Balasubramanian

Menin Inhibitors in R/R AML: Current Knowledge

11:02
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Next Questions: AML

Feat. F. Ravandi
11:22
Yale Cancer Center

Yale ASH Highlights: AML Updates

Feat. L. Mendez
16:55
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Post-Transplant Maintenance Therapy for Patients With AML:…

Feat. B. Oran
15:34
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Is AML With Monocytic Features a Separate Entity?

Feat. D. Pollyea
33:22
Yale Cancer Center

Immune Checkpoint Inhibition and Novel Therapies for Myelodysplastic…

Feat. A. Zeidan